contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-oyj-managers-transactions-antti-vuolanto-11

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.

Herantis H2-resultat och forskning framskred som förväntat. Fas Ib-studien för Parkinsons sjukdom slutförs till Q3’25, och finansieringen räcker till Q2’26. Aktien är attraktivt prissatt, men läkemedelsutvecklingen innebär betydande risker. Här är en ny analys – värd att läsa!                   Inderes              Herantis H2'24: Phase Ib completion is this year's theme - Inderes    Herantis Pharma's H2 was as expected, both in terms of numbers and trial progress.

Herantis H2’24 rörelseresultat var i linje med förväntningarna och uppgick till -2,27 miljoner euro. Företaget inledde en fas Ib klinisk studie med läkemedlet HER-096 för Parkinsons sjukdom, och resultaten förväntas komma under tredje kvartalet 2025. Den nuvarande finansieringen är tillräcklig för att slutföra fas Ib, förbereda för fas II och driva på partnerskapsförhandlingar. Här är en analytikers tankar om företagets resultat                    Inderes              Herantis H2'24 flash comment: Trial progress and figures were as expected  -...    Herantis' H2'24 operating result was -2.27 MEUR, in line with our expectations. The company initiated a Phase Ib clinical trial in Parkinson's disease with HER-096 during the reporting period.

Herantis rapporterade att den första patienten med Parkinsons sjukdom fick en testdos av läkemedlet i fas 1b kliniska studie. Här är analytikerns kommentarer om saken.                    Inderes              Herantis Pharma Phase 1b clinical trial is progressing - Inderes    Herantis reported in a press release that the first patient with Parkinson's disease received a test dose of the drug in the second part of the Phase 1b clinical trial.

Antti Vuolanto, VD för Herantis Pharma, berättar om bioteknikföretaget som en investeringsmöjlighet.                    Inderes              Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024 -...    Time: 2024-12-03 13:50 Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.                  Inderes              Clinical phases of drug development - Inderes    We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they...

Pia intervjuade chefsanalytiker Antti Siltanen och de diskuterade självklart detta företag.  We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.                   Inderes              Herantis Pharma: Disease-modifying drug for Parkinson’s - Inderes    Time: 2024-06-26 11:53 We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is...                             Content: 00:00 Intro  00:16 What does Herantis do?  00:52 How does HER-096 work?  01:20 Risks  03:19 Competing drug candidates  04:57 Capital adequacy and funding options  06:23 Probability of commercialization  07:12 When to expect profit generation?

Herantis Pharma är ett finländskt bioteknikföretag som specialiserar sig på läkemedelsforskning och utvecklar behandlingar för flera sjukdomar, såsom Parkinsons sjukdom, skleros och bröstcancer. Företaget har en bred produktportfölj i olika kliniska faser. Herantis Pharma bildades genom en sammanslagning av Hermo Pharma och Laurantis Pharma och har sitt huvudkontor i Esbo.  Många har säkert höga förväntningar på det här företaget. Visst finns det risker, men också stor potential. Jag behöver inte berätta mer om företaget eftersom en av Inderes’ bästa aktieanalytiker har gjort en ny utmärkt och lättläst analys av företaget, där du hittar all eller nästan all information du söker om företaget. Här är analysen gjord av analytikern @antti.siltanen: Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson’s disease. The risk level of the stock as an investment is very high, as the likelihood of successful drug development is still low due to the early development phase. As a counterbalance, the market for Parkinson’s disease is large and no disease-modifying drugs are available yet. Our DCF model suggests that the stock is attractively priced. Value creation can also materialize through a development and commercialization agreement or an acquisition. We initiate coverage with an Accumulate recommendation and a target price of EUR 2.2.                   Inderes              Herantis Pharma initiation of coverage: Early stage drug development requires...    Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease.

Herantis Pharma

Herantis Pharma PlcCompany release 27 March 2025 at 14:30 EETHerantis Pharma Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName...

Herantis Pharma PlcCompany release 27 March 2025 at 14:30 EETHerantis Pharma Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Antti VuolantoPosition: Chief Executive OfficerIssuer: Herantis Pharma OyjLEI: 743700W4CQVYAT3WKK38Notification type: INITIAL NOTIFICATIONReference number: 101958/4/4____________________________________________Transaction date: 2025-03-26Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000087861Nature of transaction: ACQUISITIONTransaction details(1): Volume: 5000 Unit price: 1.4 EURAggregated transactions (1):Volume: 5000 Volume weighted average price: 1.4 EUR____________________________________________For more information, please contact:Tone Kvåle, CFOTel: +47 915 19576Email: <a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified Advisor: UB Corporate Finance Oy, Finland: +358 9 25 380&nbsp;225<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>Company website: www.herantis.com

Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto

Sekretessinställningar